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Abstract
Background: The dynorphin-kappa opioid receptor (KOR) system regulates glial proliferation after sciatic nerve
injury. Here, we investigated its role in cell proliferation following partial ligation of infraorbital nerve (pIONL), a
model for trigeminal neuropathic pain. Mechanical allodynia was enhanced in KOR gene deleted mice (KOR-/-)
compared to wild type mice. Using bromodeoxyuridine (BrdU) as a mitotic marker, we assessed cell proliferation in
three different areas of the trigeminal afferent pathway: trigeminal nucleus principalis (Vp), trigeminal root entry
zone (TREZ), and trigeminal ganglion (TG).
Results: In KOR-/- mice or norBNI-treated mice, the number of proliferating cells in the Vp was significantly less
than in WT mice, whereas cell proliferation was enhanced in TREZ and TG. The majority of the proliferating cells
were nestin positive stem cells or CD11b positive microglia in the Vp and macrophages in the TG. GFAP-positive
astrocytes made a clear borderline between the CNS and the PNS in TREZ, and phosphorylated KOR staining (KOR-
p) was detectable only in the astrocytes in CNS in WT mice but not in KOR-/- or norBNI-treated mice.
Conclusions: These results show that kappa opioid receptor system has different effects after pIONL in CNS and
PNS: KOR activation promotes CNS astrocytosis and microglial or stem cell proliferation but inhibits macrophage
proliferation in PNS. The trigeminal central root has a key role in the etiology and treatment of trigeminal
neuralgia, and these newly identified responses may provide new targets for developing pain therapies.
Background
Trigeminal nerve injury often results in debilitating
chronic orofacial pain states such as trigeminal neural-
gia. However, underlying mechanisms have not been
completely elucidated, and the outcomes of pharmacolo-
gical or surgical treatments are often disappointing [1].
To address this gap, we recently devised a mouse model
of trigeminal neuropathic pain, using a partial ligation of
infraorbital nerve (pIONL) that induces allodynic
response to tactile stimuli within the area innervated by
infraorbital nerve (ION), with substantial changes in
glial proliferation and neuropeptide expression in the
trigeminal ganglion and caudal medulla [2]. A strong
role for the dynorphin/kappa opioid receptor (KOR) sys-
tem has previously been found during responses to scia-
tic nerve ligation [3]. Here we use the pIONL trigeminal
model to identify the role of the KOR system in
mechanisms of trigeminal neuropathy.
Somatic sensory information enters the central ner-
vous system (CNS) via the trigeminal root entry zone
(TREZ), the interface between the peripheral nervous
system (PNS) and CNS, where sensory axons span an
environment consisting of Schwann cells in the PNS
and astrocytes, oligodendrocytes and microglia in the
CNS [4]. The TREZ appears to play a crucial role in tri-
geminal neuralgia etiology and treatment, because clini-
cal studies have shown beneficial effects of treatments
that target this area. For example, surgical microvascular
decompression [5-7], glycerol rhizotomy [8] or gamma
knife radiosurgery [8,9], all target the trigeminal root
and entry zone. In spite of these results suggesting the
importance of the TREZ in control of chronic trigeminal
pain, there are very few studies characterizing the anato-
mical changes in this area following nerve injury. * Correspondence: xum@u.washington.edu
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addictive properties of opiate alkaloids and are the tar-
gets of endogenous opioid peptides. Our previous stu-
dies have shown that the endogenous opioid dynorphin
was released following sciatic nerve injury, and sustained
dynorphin release stimulated kappa opioid receptors to
cause astroglial activation and proliferation in the spinal
cord [3,10]. Blockade of kappa opioid system exacer-
bated the allodynic response and prevented astroglial
activation and proliferation ins p i n a lc o r da f t e rp a r t i a l
sciatic nerve ligation (pSNL). Opiate alkaloids are mostly
immunosuppressive in vivo, whereas opioid peptides
such as b-endorphin and Met-enkephalin display multi-
ple immunomodulatory effects [11,12] Opioid peptides
are also involved in pain control during inflammation
[13]. However, few studies have examined the influence
of the kappa opioid system and blockade of kappa
opioid receptor function in animal models of neuro-
pathic pain after trigeminal nerve injury [2,14]. The cur-
rent study was performed to identify the spatial pattern
of cell proliferation along the nociceptive pain pathway
including the trigeminal nucleus principalis (Vp), tri-
geminal root entry zone (TREZ) and trigeminal ganglion
(TG) in comparison of wild type (WT), KOR knock out
(KOR-/-) and KOR antagonist (norbinaltorphimine,
norBNI) treated mice. We also examined allodynia and
facial rubbing behaviors to assess the correlation
between the cell proliferation pattern and the behavioral
changes after pIONL.
Results
Behavior and general observations
Evoked mechanical allodynia following pIONL
One day before surgery, the withdrawal threshold to
mechanical stimulation of the whisker pad was mea-
sured to assess the basal threshold (Fig. 1). Before
pIONL surgery, WT and KOR-/- showed similar
responses to the von Frey filaments, responding with a
threshold for allodynic response around 1.0 g (e.g. no
allodynia). One day after surgery, the withdrawal thresh-
old was significantly decreased on the ipsilateral side in
both WT and KOR-/- mice (P < 0.05). One week after
pIONL, WT mice with pIONLh a ds i g n i f i c a n t l y
increased mechanical threshold, whereas KOR-/- pIONL
group showed much slower recovery and significantly
greater allodynic response than WT pIONL group. On
the twenty fifth day after surgery, the kappa opioid
receptor agonist U50,488 was injected intraperitoneally
at 10 mg/kg in four experimental groups of mice (Fig. 1
B). The von Frey hair force remained at baseline for
sham groups and U50,488 completely recovered the
allodynia in WT pIONL group, but had no effect on
allodynic responses in the KOR-/- pIONL group (as
expected). These results suggest that the allodynic
response induced by pIONL could be blocked by kappa
opioid receptor activation.
Non-evoked behavior (isolated face rubbing)
The spontaneous face-rubbing behavior was video-
recorded for 15 min on preoperative day 1 (baseline)
and during postoperative day1 to day 6 (Fig. 2). The
duration of face-rubbing behavior was elevated for both
WT and KOR-/- pIONL groups on the first day after
surgery compared to the baseline and sham operated
groups. In addition, KOR-/- pIONL group showed
longer duration of face-rubbing behavior than that of
WT pIONL group on the postoperative day 1 (p <0 . 0 5 ,
ANOVA followed by Student-Newman test, n = 8 per
group). The duration of face-rubbing behavior peaked at
postoperative day 1. After that, facial rubbing gradually
r e c o v e r e dt ot h eb a s a ll e v e l .T h e r ew a sn os i g n i f i c a n t
increase of the face-rubbing behavior in either WT or
KOR-/- sham operated groups at any time point.
Effects of KOR inhibition on astrocytic Responses
We measured anatomical data in Vp, TREZ and TG at 3
regions for WT mice, KOR-/- and norBNI-treated, at 8
days after pIONL, as shown Fig. 3 (GFAP staining).
Astrocytic response to pIONL in Vp and Trigeminal root
entry zone
GFAP immunoreactive (IR) astrocytes were most promi-
nent at the boundary of the Trigeminal root entry zone
(TREZ), where they formed a distinct layer separating
C N Sa n dP N St i s s u e( F i g .3& 4 ) .W ef o u n dt h a tG F A P -
IR increased in the ipsilateral TREZ of WT mice, espe-
cially on the CNS side immediately adjacent to the
boundary at 8 days after pIONL (Fig. 4A-E) and quanti-
fication of GFAP-IR was performed within this area.
Quantification showed that pIONL significantly
increased the intensity of GFAP-IR in ipsilateral TREZ
in WT mice compared with sham operated mice or
with the contralateral TREZ (Fig. 4A, B, C, F). In con-
trast, neither KOR-/- nor NorBNI-treated mice showed
significant changes in the expression pattern of GFAP-
IR between ipsilateral and contralateral side of TREZ
(Fig. 4D, E, F). Thus, the increase in the intensity of
GFAP-IR astrocytes in the TREZ was blocked by the
deletion of KOR or by norBNI pretreatment. Similarly,
CNS astrocytosis was prominent in Vp of WT mice, but
pIONL did not induce astrocytosis in KOR-/- or norBNI
treated mice (data not shown).
KOR activation in trigeminal root entry zone
We previously established that activation of KOR results
in G-protein receptor kinase mediated phosphorylation
of KOR that can be readily detected using a phosphor
selective antibody, KOR-p-IR [15]. Stimulation of endo-
genous dynorphin release can be evoked by exposure to
behavioral stressors [16] or neuropathic pain [3]. These
stimuli increase KOR-p-IR, and this response can be
blocked by prior norBNI treatment or gene deletion of
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pIONL, the most intense KOR-p staining was localized
along the CNS-PNS boundary, and KOR-p-IR intensity
was measured in this area (Fig. 5A). KOR-p staining
increased in the ipsilateral side compared to contralat-
eral side 8 days following pIONL (Fig. 5B, C). KOR acti-
vation in the ipsilateral TREZ was blocked by the
deletion of KOR or by NorBNI treatment (Fig. 5D, E, F).
Double immunohistochemictry revealed that KOR-p-IR
is expressed by astrocytes (GFAP) in TREZ of WT mice
(Fig. 5G, H, I).
Cell Proliferation along the Trigeminal Pathway
To understand the contribution of cell proliferation in
trigeminal afferent pathway to neuropathic pain after
pIONL, we analyzed the proliferation pattern using
BrdU staining at 8 days after pIONL. We focused our
analysis on three different areas: ION region in Vp (Fig.
6), the TREZ boundary between PNS and CNS (Fig. 7),
Figure 1 (A) Response thresholds of ipsilateral whisker pad to usually innocuous tactile (von Frey Hair) stimuli in WT sham, WT
pIONL, KOR-/- sham, and KOR-/- pIONL mice during 25 days after partial infraorbital nerve ligation. After pIONL, both WT and KOR-/-
mice developed allodynic response as evident from the decreased thresholds to tactile stimulation compared with WT and KOR-/- mice that
received sham-ligation surgeries. One week after pIONL, WT mice with pIONL began to show the increase of the mechanical threshold, whereas
KOR-/- pIONL group showed much slower recovery and significantly greater allodynic response than WT pIONL group. (B)On the 25
th day after
surgery, we injected the kappa opioid receptor agonist U50,488 intraperitoneally at 10 mg/kg in each group of mice. The von Frey hair force
returned to baseline in WT pIONL group, but not in KOR-/- pIONL group. U50,488 injection did not affect the mechanical threshold in sham
operated groups. Asterisks indicate significant decreases in the threshold to stimuli by the von Frey hair applied to ipsilateral side of whisker pad
in KOR-/- pIONL group compared to WT pIONL group (p < 0.05, ANOVA followed by Student-Newman test). Data are presented as the mean ±
SEM von Frey hair threshold in grams; n = 8 per time point).
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terns of BrdU staining.
Trigeminal Principal Nucleus (Vp)
In the Vp (the area is surrounded by red rectangle in Fig.
6A), the number of BrdU-IR nuclei significantly increased
in ipsilateral side compared to contralateral side or sham
operated mice 8 days after pIONL (Fig. 6A, B, C, F).
Interestingly, the number of BrdU-IR nuclei was less in
KOR-/- or norBNI treated mice than in WT (Fig. 6B, D,
E, G, H). Double immunohistochemistry showed that the
vast majority of BrdU-IR co-labeled with nestin (Fig. 6K,
N) and CD11b (Fig. 6J, M), markers of neuronal stem cell
and microglia, respectively, but not with GFAP for astro-
cytes (Fig. 6I, L) in this brain region.
Trigeminal Root Entry Zone (TREZ)
BrdU-IR did not show robust increase in TREZ and
adjacent area of the border when compared to TG and
Vp in WT mice (Fig. 7A, B, C, F). On the other hand,
BrdU positive nuclei in KOR-/- mice or norBNI pre-
treated mice showed significant increase in the ipsilat-
eral side after pIONL (Fig. 7D, E, G, H). Double immu-
nohistochemistry revealed that these BrdU positive
nuclei were expressed by nestin positive stem cells (Fig
7K, O) and CD 11b positive microglia(Fig 7L, P) but not
by either astrocytes (GFAP-IR in the CNS side, Fig 7I,
M) or by Schwann cells (S100beta-IR in the PNS side,
Fig 7J, N) in this area.
Trigeminal Ganglion (TG)
In ION region of TG(the area is surrounded by red rec-
tangle in Fig. 8A), the number of BrdU positive nuclei
robustly increased in perineuronal area compared with
contralateral side or sham TG at 8 days after pIONL in
WT mice (Fig. 8B, C, F). Furthermore, in the ipsilateral
side of ION in KOR-/- and norBNI treated mice, BrdU-
IR was nearly 2.5 times greater than that in WT (Fig.
8 B ,D ,E ,G ,H ) .D o u b l ei m m u n o h i s t o c h e m i s t r ys h o w e d
that the vast majority of these nuclei corresponded to
macrophages but not satellite cells or Schwann cells
because these BrdU positive nuclei were surrounded by
CD11b-IR but not GFAP-IR or S100beta-IR (Fig. 8I, J,
K, L, M, N).
Discussion
The present study demonstrated that impairment of the
KOR system enhances the allodynic response and delays
functional recovery from partial infraorbital nerve liga-
tion. This result is consistent with our previous study
showing dynorphin KOR system regulates neuropathic
pain responses following partial sciatic nerve ligation in
m i c e[ 3 ]a n ds h o w st h a tt h es p i n a la n dt r i g e m i n a ls y s -
t e m sa r es i m i l a r .T h ec u r r e n ts t u d yf u r t h e rf o c u s e do n
the role of the KOR system on cell proliferation along
trigeminal nociceptive pathway, the first time this has
been investigated. The most novel finding of this study
Figure 2 Face rubbing after pIONL. The total time for isolated face-rubbing episode during a 15 min observation period. The spontaneous
face-rubbing behavior was recorded for 15 minutes on preoperative day 1 (baseline), and from postoperative day1 to day 6. The duration of
face-rubbing behavior was elevated for both WT and KOR-/- pIONL groups on the first day after surgery compared to the baseline and sham
operated groups. KOR-/- pIONL group showed longer duration of face-rubbing behavior than that of WT pIONL group on the postoperative day
1( p < 0.05, ANOVA followed by Student-Newman test, n = 8 per group). The duration of face-rubbing behavior peaked at postoperative day 1
and this increased facial rubbing gradually recovered to the basal level.
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cell proliferation in the CNS but enhanced it in the
PNS. Thus, increased allodynia in the trigeminal system
may involve inhibition of CNS astrocytosis, reduced
CNS microglial proliferation and enhanced macrophage
invasion and proliferation in the PNS.
Previous study has shown that pIONL markedly
increased the number of BrdU positive nuclei in caudal
medulla of WT mice [3]. Recent studies have also indi-
cated that orofacial nociceptive information could be
more highly modulated in Vp than in other trigeminal
brainstem sensory nuclei [17,18] and so we have assayed
the Vp in the current work. Here, pIONL induced a
marked increase of BrdU positive cells in ipsilateral Vp
in WT mice and the majority of the proliferating cells
were nestin positive stem cells or double-labeled by
microglial marker CD11b. This result suggests that Vp
is also involved in the pathological changes following
pIONL. Surprisingly when KOR was impaired in knock-
out mice or by NorBNI treatment, proliferation of stem
cells and microglia was not evident in Vp. In this region,
the intensity of GFAP-IR was also decreased in KOR-/-
and norBNI treated mice compared to WT mice. The
consequences of this lack of the astrocyte activation
would likely result in an impairment in extracellular glu-
tamate regulation. An impairment of the glial-neuronal
network that controls neuronal physiologic activities,
promotes neurogenesis and secretion of neurotrophins
is also probable [19-21]. A lack of the astrocyte activa-
tion might also cause the decreased number of prolifer-
ating stem cells and microglia in KOR-/- and norBNI
treated mice. Together, those changes would be enhance
nociceptive response after pIONL.
In the CNS compartment of TREZ in WT mice, the
number of BrdU positive nuclei did not show statisti-
cally significant increase after pIONL when compared
with the ipsilateral and the contralateral TREZ. [22]
demonstrated that peripheral nerve injury induces cell
proliferation in spinal dorsal root entry zone (DREZ) at
day 2-3 following nerve surgery and after that, there was
a sharp decline in the number of proliferating cells. At 7
days after surgery, cell proliferation was almost absent
in DREZ. Our observation point was at day 8 after sur-
gery and also did not show cell proliferatioin then in
WT mice. In KOR-/- mice or norBNI treated mice, the
number of proliferating cell was significantly greater
than that in WT mice. Even in KOR-/- sham operated
mice, the number of BrdU positive cells was more than
that in WT pIONL mice. However, there was no signifi-
cant difference between ipsilateral and contralateral
TREZ in KOR-/- or norBNI treated mice. Future studies
will be necessary to determine whether this greater
number of proliferating cell in the TREZ in KOR-/-
mice or norBNI treated mice indicate that the basal cell
proliferation is higher than WT. Possibly both have an
initial increase at 2-3 days after surgery, but the decline
of proliferating cells is slower in KOR-/- mice than WT.
In the present study, double labeling revealed that BrdU
positive nuclei were expressed by microglia or nestin-
expressing stem cells but not in astrocytes in the CNS
compartment of TREZ. This result was consistent with
previous studies [22-24]. There were also proliferating
cells in the PNS compartment of TREZ, and the major-
ity of these proliferating cells were CD11b positive
macrophages.
In the trigeminal ganglion, satellite cells and Schwann
cells are the predominant non-neuronal cells, but there
are also macrophages that infiltrate the region following
nerve injury. Previous studies have shown that cell pro-
liferation occurs in Schwann cells [25] and in macro-
phages near the cell bodies of injured neurons in TG
during Wallerian degeneration [26]. Schwann cells pro-
duce a number of neurotrophic factors that support the
survival of injured neurons [27]. In addition, they also
promote macrophage infiltration to the injured nerve
Figure 3 Orientation of VP, TREZ, TG. Key areas for our analyses
are shown here: (1) the trigeminal principle nucleus (Vp), (2) The
root entry zone (TREZ) where central glia are in the CNS side (GFAP,
red), and Schwann cells on the ganglion side, and (3) trigeminal
ganglion (TG). The cell bodies for infraorbital nerve (ION) occur in
the distal parts of the combined V1/V2 but not in V3. Yellow boxes
show sites for quantification.
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[33-35]. In the present study, we observed increased
BrdU positive cells in the ipsilateral ION region in TG
at day 8 after pIONL in all injured groups. The number
of proliferating cells was significantly greater in KOR-/-
and norBNI treated mice than that in WT mice, sug-
gesting that the lack of kappa opioid system enhanced
cell proliferation in the TG. Double immunohistochem-
istry showed that these BrdU positive cells were all
expressed in CD11b positive macrophages. Increase in
the density of macrophages in DRGs after peripheral
nerve lesions has previously been described [36-39] and
that has been shown to contribute to neuronal survival
in the short term and generation of chronic neuropathic
pain by triggering neuronal impulses.
The endogenous kappa selective peptide, dynorphin,
has been shown to increase macrophage superoxide pro-
duction [40], modulate macrophage oxidative burst [41],
Figure 4 GFAP immunoreactivity in the TREZ at day 8 after pIONL. (A), GFAP-IR in sham operated WT mice. (B, C), pIONL induced slight
increase in the intensity of GFAP staining in the ipsilateral TREZ of WT mice but not the contralateral side. (D, E), KOR-/- mice or mice pre-
treated with norBNI did not show significant upregulation of GFAP immunoreactivity in the ipsilateral TREZ, and this was the same intensity as in
the contralateral TREZ of WT pIONL mice (B) or WT sham operated mice(A). (F), Mean ± SEM pixel intensity of GFAP immunoreactivity in TREZ at
day 8 after pIONL. (*p < 0.001) Scale bars: A-E, 50 μm
Aita et al. Molecular Pain 2010, 6:8
http://www.molecularpain.com/content/6/1/8
Page 6 of 14enhance macrophage tumoricidal activity [42,43] and
increase production of the cytokine IL-1 from bone
marrow macrophages [44]. Both T cells and macro-
phages are targets for kappa agonists to produce inhibi-
tion of T-cell-mediated antibody production [12,45,46].
Both endogenous and exogenous opioids have been
found to modulate the immune response [47]. In many
cases, treatment with opioids results in an impairment
of immune function [11]. In addition, previous study
has shown that resting macrophage phagocytic activity
is depressed by treatment with μ-opioid-, δ-opioid-, and
-opioid-selective agonists, and that the inhibitory activ-
ities of these compounds can be reversed by the corre-
sponding opioid-type-selective antagonist [48]. These
studies suggest that kappa opioid receptors on macro-
phages are involved in cell proliferation after peripheral
nerve injury. The kappa opioid system may prevent the
expansion of neuro-inflammation by controlling the
activation of macrophage.
In this study, we used an antibody which detects the
phosphorylated form of kappa opioid receptor to deter-
mine the sites of endogenous dynorphin action in TG,
Figure 5 KOR activation in TREZ at day 8 after pIONL. (A), KOR-p-IR in sham operated WT mice. (B, C), increased KOR-p staining was seen
within the root entry zone on the ipsilateral side compared to contralateral side following pIONL in WT mice. KOR activation was blocked by
the deletion of kappa opioid receptor or norBNI treatment (D, E). (F), Mean ± SEM pixel intensity of KOR-p intensity in TREZ at day 8 after pIONL.
(G-I), Double immunohistochemistry for KOR-p and GFAP in the TREZ at day 8 after pIONL. KOR-p staining is completely overlapped with GFAP
staining. (*p < 0.001) Scale bars: A-E, 30 μm; G-I, 50 μm.
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Page 7 of 14Figure 6 Cell proliferation central trigeminal root at day 8 after pIONL. (A) Data came from Vp (the area shown in red box). (B, C, F), BrdU
positive cells are markedly increased in the ipsilateral Vp inWT pIONL compare to contralateral side. (B-H), in KOR-/- and NBNI pre-treated pIONL
mice, the number of BrdU positive cells significantly decreased compared to WT pIONL mice. (I-N), Different cellular markers (GFAP for satellite
cells, CD11b for microglia, nestin for neuronal stem cell) were used to identify the phenotypes of dividing cells. The majority of BrdU positive
cells were double labeled with nestin and CD11b. Only few BrdU positive nuclei were double labeled with GFAP. (*p < 0.001) Scale bars: A, 250
μm, C-H, 50 μm, I-N, 30 μm.
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Page 8 of 14Figure 7 Cell proliferation in TREZ 8 d after pIONL. (A) Data came from TREZ (the area shown in red box). (B, C, F), the number of BrdU
positive nuclei increased in both ipsilateral and contralateral TREZ following pIONL in WT compared to sham operated mice. (B-H), in the
ipsilateral TREZ, KOR-/- and norBNI treated mice showed BrdU positive nuclei more than twice as much as that in WT mice. Similar to the result
from Vp, the majority of BrdU positive nuclei was double-labeled with CD11b or Nestin in the CNS side of TREZ. Neither GFAP or S100beta-IR
was double labeled with BrdU-IR (I-P). (*p < 0.001) Scale bars: A, 250 μm, C-H, 50 μm, I-P, 30 μm.
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Page 9 of 14Figure 8 Cell proliferation in ION region in the trigeminal ganglion at day 8 after pIONL. (A) Data came from ION region in TG (the area
shown in red box). (B, C, F), pIONL induced marked upregulation of BrdU positive cells in the ipsilateral side of ION region in WT mice. (B-H), in
KOR-/- and norBNI pre-treated mice, the number of BrdU positive cells significantly increased compared to WT pIONL mice. (I-N) Different cellular
markers (GFAP for satellite cells, S100beta for Schwann cells, CD11b for macrophage) were used to identify the phenotypes of dividing cells.
Only rare cells were double labeled for BrdU and GFAP or S100beta. The majority of BrdU positive cells were CD11b positive macrophage. (*p <
0.001). Scale bars: A, 250 μm, C-H, 50 μm, I-N, 30 μm.
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the sustained release of endogenous dynorphins during
chronic pain increased KOR phosphorylation as detected
by KOR-p staining. We found that the upregulation of
KOP-p staining was seen only in the CNS side of the
TREZ and only in WT mice. The intensity of KOR-p
staining increased for the ipsilateral side of TREZ and was
blocked by the deletion of kappa opioid receptor or pre-
treatment with kappa opioid receptor antagonist norBNI
at 8 days after pIONL. Consistent with our previous stu-
dies, KOR-p staining was co-localized with GFAP staining
in the CNS side of TREZ. GFAP staining showed a similar
pattern of KOR-p staining, which was upregulated in ipsi-
lateral TREZ in WT mice after pIONL, and this upredu-
lated GFAP was not evident in KOR-/- and norBNI
treated mice. We did not find kappa opioid receptor acti-
vation in the ganglion at day 8 after pIONL. However, this
result does not automatically indicate that kappa opioid
receptor does not exist in trigeminal nerve or ganglia. The
density of kappa opioid receptor is low in immune cells
and only small subpopulations of immune cells may
express the receptor. The cell proliferative patterns
described in the various CNS and PNS locations show not
only interactions between the injured neurons but also
between non-neuronal cells residing in the affected
regions. Furthermore, our results suggested that endogen-
ous kappa opioid system modulates the proliferation of
immune cell in a different manner between PNS and CNS,
and the lack of the kappa opioid receptor leads to
enhanced allodynic response after peripheral nerve injury.
Conclusions
These results show that kappa opioid receptor system
has different effects after pIONL in CNS and PNS: KOR
activation promotes CNS astrocytosis and microglial or
stem cell proliferation but inhibits macrophage prolifera-
tion in PNS. Our demonstration of the importance of
the endogenous kappa opioid system for the activation
of astrocytes and proliferation of stem cells and immune
cells after peripheral nerve injury helps to understand
the neuroinflammatory changes in the trigeminal system
using a mouse model that causes persistent trigeminal
allodynia. The lack of astrocyte proliferation at the CNS
sites differs from CNS responses to sciatic nerve injury
[10]. This work provides new targets for development of
KOR modulating drugs for regulation of the immune
system and inflammatory reactions after peripheral
nerve injury in general, and for trigeminal neuropathic
pain in particular.
Materials and methods
Animals
Male C57Bl/6 mice (Charles River Laboratories, Wil-
mington, MA) weighing 22-32 g (12-16 weeks old) were
used in these experiments. Mice were group-housed, in
self-standing plastic cages (28 cm L × 16 cm W × 13
cm H) within the animal core facility at the University
of Washington, and maintained in a specific pathogen-
free housing unit. Mice were transferred 1 week prior to
behavior testing into a colony room adjacent to the test-
ing room to acclimatize to the testing environment.
Housing rooms were illuminated on a 12-h light-dark
c y c l ew i t hl i g h t so na t0 7 0 0 .F o o dp e l l e t sa n dw a t e r
were available ad libitum. Procedures with mice were
approved by the Institutional Animal Care and Use
Committee in accordance with the 1996 NIH Guide for
the Care and Use of Laboratory Animals.
Surgical preparation: Partial Ligation of the Infraorbital
Nerve (pIONL)
As previously described [2], the unilateral partial ligation
to the right ION was performed under direct visual con-
trol using a Zeiss surgical microscope (×10-25). The ani-
mals were anesthetized with sodium pentobarbital
(Nembutal, 80 mg/kg i.p.). They were kept warm with a
heat lamp and foil blanket, their eyes were treated with
lubricating ophthalmic ointment (Akorn, Buffalo Grove,
IL), and the top of the snout was shaved and rubbed
with iodine. The mouse was taped to a sterilized cork
board, the skin along the top of the snout was shaved
and iodine treated, and a mid-line incision was made to
expose nasal and maxillary bone. All tools were gas ster-
ilized prior to surgery and then washed and heat-treated
(glass beads at 250°C) between animals. The left ION
was initially exposed 1-2 mm rostral to infraorbital fora-
men on the maxillary bone using blunt dissection with
small scissors. The ION was gently isolated using fine
forceps without damaging nearby facial nerve branches.
Approximately 1/3 to 1/2 the diameter of the nerve was
tightly ligated with 7-0 silk suture (Surgical Specialties
Corporation, Reading, PA) by passing the suture needle
completely under the lateral aspect of the nerve and
then up through the middle. After confirming hemosta-
sis, the incision was closed using silk sutures (5-0). For
the sham-operated mice, the ION was exposed on the
left side using the same procedure without damaging
ION. The mice received one analgesic (buprenorphine,
0.05 mg/kg) treatment at the end of the surgery. The
operated mice were able to eat and drink unaided soon
after waking up, the body weight returned back to or
exceeded preoperative weights after the first week.
Behavioral testing
Stimulus-evoked responses: Mechanical allodynia
The mice were tested one day before surgery, daily dur-
ing the first postoperative week, and on alternate days
after that. All experiments were carried out in a quiet
room between 0800 and 1500 hr. Body weight was mea-
sured every time before testing. On the day of testing,
mice were habituated to handling and testing equipment
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Frey filaments (Semmes-Weinstein monofilaments,
Stoelting, Wood Dale, IL) was used for mechanical sti-
mulation of ipsilateral infraorbital nerve territory. The
filaments produced a bending force of 0.02, 0.04, 0.07,
0.16, 0.4, 0.6, 1.0 and 1.4 gm. The mice stood on a
metal mesh with a porous plastic cup (diameter: 8 cm)
covering them. Von Frey hairs were then inserted from
below through the mesh. The stimuli were applied
within the infraorbital nerve territory, near the center of
the vibrissa pad, on the hairy skin of the ipsilateral side.
The response threshold was determined by a brisk with-
drawal of the head. The stimulation always began with
the filament producing the lowest force and stopped
when threshold was found. Unresponsive mice received
a maximum stimulus score of 1.4 gm.
Non-evoked Behavior: Facial rubbing behavior
Mice were placed individually in small transparent plas-
tic cages (14 cm × 16 cm × 13 cm) without bedding. A
video camera was placed 0.8 m at the side of the cage
and positioned so that the image of the mouse head was
observed. Mice were habituated in the cage for 15 min
and then recorded 15 min per day. Duration of face rub-
bing actions was recorded as the total time that the
forelimbs contacted facial region and ears.
Immunohistochemistry
Mice were anesthetized with sodium pentobarbital (100
mg/kg i.p.) and intracardially (i.c.) perfused with 4%
para-formaldehyde in PB (phosphate buffer, 0.1 M
sodium phosphate, pH 7.4). The trigeminal ganglia (TG)
were dissected, postfixed for 2 hours, cryoprotected with
solution of 30% (w/v) sucrose in PB at 4°C overnight
and cut into series of 30 μm sections (brainstem) or 10
μm serial sections (TG plus TREZ and attached princi-
pal nucleus region of brainstem) with a cryostat micro-
tome. TG sections were mounted onto Supefrost/Plus
slide glass (Fisher Scientific) and frozen at -20°C until
use. Sections were washed 3 times in 0.1 M PBS (phos-
phate buffer saline, pH7.4), blocked in PBS containing
0.1% Triton X-100 and 5% normal goat serum for 1 hr,
and incubated overnight with primary antibodies. Pri-
mary antibody concentrations were as follows: rabbit
anti-phosphorylated kappa opioid receptor (20 μg/ml)
generated as previously described (McLaughlin et al.,
2004), rat anti-CD11b (1:200, Serotec, Oxford, UK), rab-
bit anti-GFAP (1:1000, Dako, Denmark), mouse anti-
nestin (Abcam, Cambridge, MA) and mouse anti-BrdU
(6 μg/ml, Millipore, Temecula CA) or rat anti-BrdU (1:
50 Abcam Cambridge, MA). For BrdU staining, sections
were treated with 2N HCl for 60 min at 37°C, followed
by rinsing in 0.1 M borate buffer before incubation
overnight with primary antibody. Sections were then
washed with PBS, and detection was carried out using
the rhodamine (TRITC) or fluorescein (FITC)
conjugated fluorescent secondary antibodies (1:250;
Jackson ImmunoResearch, West Grove, PA). Antibodies
were diluted in a solution containing 0.1% Triton X-100
and 1.5% normal goat serum in PBS. The finished sec-
tions were rinsed in PBS for 30 min, and then mounted
on Superfrost/Plus slide glass (Fisher Scientific) with
Vectashield mounting medium (Vector Laboratories,
Burlingame, CA) and sealed with nail polish. The sec-
tions were viewed with a Nikon Eclipse E600 fluores-
cence microscope (Tokyo, Japan) or a Leica SL confocal
microscope located in the W.M. Keck Imaging Facility
at the University of Washington.
Chemicals (Drugs Sources, Dosage, Timing)
NorBNI was obtained from the National Institute on
Drug Abuse drug supply program (National Institutes of
Health, Bethesda, MD). NorBNI is an antagonist for
KOR and it was given at 10 mg/kg (i.p.). It is active for
a week, but uniformity of dosage is best achieved by giv-
ing the drug every 3 days (McLaughlin et al., 2003).
U50,488 was obtained from Sigma, St. Louis, Mo USA.
U50,488 is an agonist for KOR and it was given at 10
mg/kg (i.p.) 30 minutes before behavioral tests were
done. The doses of NorBNI and U50,488 were chosen
based on our previous publication (Xu et al., 2004). 5-
Bromo-2’-deoxyuridine (BrdU) was from Sigma (St.
Louis, MO). Mice were injected intraperitoneally with
BrdU solution in saline (100 mg of BrdU per kilogram
of body weight) once a day for 7 days starting from the
day of partial infraorbital nerve ligation. BrdU is a thy-
midine analog that is specifically incorporated into DNA
during DNA synthesis that can be used as a marker for
proliferation.
Data Analysis
M e c h a n i c a la l l o d y n i ad a t aw e r ea n a l y z e db yA N O V A .
For all groups, pre- and post-operative behavior for
intra-animal comparisons as well as group comparisons
were made. Statistical significance determined by
ANOVA was then further analyzed with Student-New-
man-Keuls test or Student’s t test for significant pair-
wise comparisons. Response data are presented as
means ± SEM of the animal treatment group, with sig-
nificance set at p < 0.05. Estimations of the total num-
ber of nuclei positive for B r d Uw a sc a l c u l a t e da ta n
objective magnification of ×20 in an ocular frame (area
0.34 mm
2). In order to count cells in the three different
areas, the frame was oriented in the following ways. The
trigeminal tract: the frame was oriented so that the thin
line of Lissauer’s tract and the adjacent grey matter
were included. TREZ: the frame was placed so that the
boundary of CNS and PNS and the adjacent PNS region
were included. ION: the frame was placed in the ION
region, which was confirmed by our previous study
using ATF3 expression [2]. Altogether, counts were
made in at least 6 complete frames from each area and
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frames within each tissue compartment were calculated.
The quantitative data on numbers of proliferating cells
following pIONL was analysed with student’s t-test for
each area with significance set at p < 0.05.
The density of immunoreactivity on each slide of TG
was evaluated using NIH image J. For structures in
which immunoreactivity was upregulated after nerve
injury, mean optical density (brightness) was determined
after subtracting background grey levels. Data were
reported as means ± SEM. Statistical differences (p <
0.05) were determined by t-test.
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